Oligomerix: Tau tapping

By Jesse Beckstein Staff Writer | Dec 15, 2008 | 8:00 AM GMT

The primary focus of most drug discovery in Alzheimer's disease has been on the large intraneuronal plaques of beta amyloid or the neurofibrillary tangles of tau protein. Oligomerix Inc. is working on microtubule-associated protein tau (MAPT)(tau)(FTDP-17), but a step earlier, before the tangles form. The company believes its work may result in disease-modifying therapeutics, as well as assays for early diagnosis.